EUROIMMUN has introduced two ELISAs for the detection of IgM and IgG antibodies against Oropouche virus. Oropouche virus is the causative agent of Oropouche fever, an emerging disease which manifests with dengue-like symptoms such as sudden onset of high fever, myalgia, rash, joint pain and vomiting. The virus circulates in Central and South America and the Caribbean and is transmitted to humans primarily by bites of Culicoides paraensis midges.

Oropouche fever must be clinically differen-tiated from other common vector-borne diseases in the same regions, such as malaria, dengue, chikungunya, Zika and yellow fever.

According to information from the Centers of Disease Control and Prevention (CDC) in the USA, Oropouche virus is a candidate for possible further urban spread and therefore warrants increased surveillance and diagnostics.

The Anti-Oropouche Virus ELISAs are based on microplate wells coated with recombinant structural antigens of the Oropouche virus for sensitive and specific antibody detection. They can be incubated in parallel to other EUROIMMUN ELISAs for infectious diseases due to largely exchangeable reagents and standardised incubation conditions. The assays can be fully automated on established instruments such as the EUROLabWorkstation ELISA or the EUROIMMUN Analyzer I or I-2P.

The EUROIMUN Anti-Oropouche Virus IgM and IgG ELISAs are currently available for research use only and serve as useful tools for epidemiological studies to aid outbreak responses and prevention. The new ELISAs complement EUROIMMUN’s portfolio of serological tests for emerging viral and parasitic diseases, which is one of the most extensive available worldwide.

For more information, visit: www.euroimmun.com
Digital issue: Please click here for more information